Rating Change
JP Morgan analysts initiated coverage on BridgeBio Oncology Therapeutics Inc. (NASDAQ:BBOT) with a Overweight rating on July 08, 2026.
new coverageNASDAQ:BBOT
JP Morgan Initiates Coverage on BridgeBio Oncology Therapeutics Inc. (BBOT) with Overweight
Rating Change JP Morgan analysts initiated coverage on BridgeBio Oncology Therapeutics Inc. (NASDAQ:BBOT) with a Overweight rating on July 08, 2026. Market Context BridgeBio…
Market Context
BridgeBio Oncology Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $8.43 with a market capitalization of $1.0B.
Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for BridgeBio Oncology Therapeutics Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for BridgeBio Oncology Therapeutics Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 08, 2026 | JP Morgan | Overweight | N/A |
| May 11, 2026 | Canaccord Genuity | Buy | N/A |
| Mar 06, 2026 | HC Wainwright & Co. | Buy | N/A |
| Feb 11, 2026 | Stifel | Buy | N/A |
| Jan 09, 2026 | Raymond James | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View BBOT Stock Page
Frequently Asked Questions
What does a Overweight rating mean for BBOT?
A Overweight rating from JP Morgan reflects the analyst's outlook on BridgeBio Oncology Therapeutics Inc. (NASDAQ:BBOT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BBOT forecast page.